| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
There have been no biomarkers found which can predicting progression to severe cutaneous adverse drug reactions (SCARs). Therefore, there is an urgent need for reliable and standard laboratory tests for identifying patients at higher risk of developing SCARs. A variety of cytokines/chemokines in the serum in patients who presented with clinical symptoms suggestive of SCARs were retrospectively measured using multiplex biometric immunoassay. Our results showed that several biomarkers altered in combinations depending on the clinical type of SCARs such as Stevens-Johnson syndrome and toxic epidermal necrolysis, although each biomarker was not sufficiently sensitive or specific on its own.
The evaluation of these markers in combinations could increase the diagnostic and prognostic utility for the prediction of SCARs. Furthermore, the measurements of these selected markers at the initial stage could contribute to the appropriate selection of treatment modalities for SCARs.
|
